Sorafenib and thyroid cancer

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Edwards BK, Noone AM, Mariotto AB, et al. SEER cancer statistics review 1975-2011. Available from: http://seer.cancer.gov/csr/1975_2011 [Last accessed 13 May 2014]
   Google Scholar
• Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin 2013;63:373-94
   Web of Science ®Google Scholar
• LiVolsi VA. Papillary thyroid cancer: an update. Mod Pathol 2011;24:S1-9
   PubMed Web of Science ®Google Scholar
• Wells S. Principles and practice of oncology-updates. Targeted Ther Thyroid Cancer 2012;26(3):1-27
   Google Scholar
• Ganly I, Ricarte FJ, Eng S, et al. Genomic Dissection of Hürthlecell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013;98(5):E962-72
   Web of Science ®Google Scholar
• Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with Adriamycin. N Engl J Med 1974;290:193-7
   PubMed Web of Science ®Google Scholar
• Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid cancer. Cancer 1985;56:2155-60
   PubMed Web of Science ®Google Scholar
• Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358; Article ID 542358, 13 pages
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: thyroid cancer. V.2.2013. Available from: www.nccn.org [Last accessed 13 May 2014]
   Google Scholar
• Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CACHIT) Group. Thyroid 2000;10:587-94
   PubMed Web of Science ®Google Scholar
• Haraldsdottir S, Shah MH. New era for treatment in differentiated thyroid cancer. Lancet 2014. Epub 24 April 2014. Available from: http://thelancet.com [Last accessed 5 May 2013]
   Google Scholar
• American Thyroid Association (ATA) Guidelines Taskforce on thyroid nodules and differentiated cancer. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
   PubMed Web of Science ®Google Scholar
• Arturi F, Russo D, Schlumberger M, et al. Iodide symporters gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83:2493-6
   PubMed Web of Science ®Google Scholar
• Bruno R, Giannasio P, Ronga G, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest 2004;11:1010-14
   Google Scholar
• Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7thed. NewYork: Springer; 2010. 87-97
   Google Scholar
• Lang GB, Law TT. The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms. Oncologist 2011;16:458-66
   PubMed Web of Science ®Google Scholar
• Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence of constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99
   PubMed Web of Science ®Google Scholar
• Lassalle S, Hofman V, Ilie M, et al. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefullness as diagnostic, prognostic and the agnostic applications. Curr Med Chem 2010;17:1839-50
   PubMed Web of Science ®Google Scholar
• Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Brit J Cancer 2007;96:16-20
   PubMed Web of Science ®Google Scholar
• Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAFV600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010;95:4197-205
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:63-1454-7
   Web of Science ®Google Scholar
• Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-64
   PubMed Web of Science ®Google Scholar
• Zhu Z, Gandhi M, Niforova MN, et al. Molecular profile and clinical pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71-7
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-80
   PubMed Web of Science ®Google Scholar
• Motoi N, Sakamoto A, Yamochi T, et al. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 2000;196:1-7
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Dis 2006;5:835-44
   PubMed Web of Science ®Google Scholar
• Perez CA, Santos ES, Arango BA, et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;34:736-45
   PubMed Web of Science ®Google Scholar
• Lowinger TB, Riedel B. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8:2269-78
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. on behalf of the DECISION investigtors. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014. Epub 24 April 2014. Available from: http://thelancet.com [Last accessed 5 May 2013]
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell cancer. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Kasid U, Dritschillo A. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 2003;22:5876-84
   PubMed Web of Science ®Google Scholar
• Smith RA, Barbosa J, Blum CL, et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett 2001;11:2775-8
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Adnane L, Trail PA. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:42637
   Web of Science ®Google Scholar
• Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on Sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Ahmed A, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31
   PubMed Web of Science ®Google Scholar
• Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600-4
   PubMed Web of Science ®Google Scholar
• Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19:251-8
   PubMed Web of Science ®Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9
   PubMed Web of Science ®Google Scholar
• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604
   PubMed Web of Science ®Google Scholar
• Dadu R, Waguespack SG, Sherman SI, et al. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 2014;19:477-82
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicenter, randomized, double-blindplacebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroidcancer (SELECT). ASCO Annual Meeting. Abstract LBA6008 Presented 2 June 2014
   Google Scholar
• Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366(3):207-15
   PubMed Web of Science ®Google Scholar